NRD
LGND icon

Nebula Research & Development’s Ligand Pharmaceuticals LGND Stock Holding History

Nebula Research & Development’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,300
Closed -$461K – 938
2024
Q1 		$461K Buy
+6,300
New +$464K 0.1% 382
2023
Q4 		– Sell
-5,379
Closed -$322K – 777
2023
Q3 		$322K Buy
+5,379
New +$354K 0.17% 258

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Nebula Research & Development's LGND Position: Q2 2024 in Review

Nebula Research & Development sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 6,300 shares — an estimated $461K sold.

Nebula Research & Development first reported a position in LGND in Q3 2023 and held it in 2 quarters. The position peaked at $461K in Q1 2024. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

  • Nebula Research & Development reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Nebula Research & Development sold 6,300 Ligand Pharmaceuticals shares in Q2 2024, an estimated $461K.
  • Nebula Research & Development first reported a position in Ligand Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Nebula Research & Development's Ligand Pharmaceuticals position peaked at $461K in Q1 2024.
  • 234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on Nebula Research & Development's 13F filing for Q2 2024, filed 14 Aug 2024.